Dr. Choueiri on Existing Therapies for Kidney Cancer

Toni Choueiri, MD
Published: Tuesday, Apr 25, 2017



Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the current therapies for patients with kidney cancer.

Sunitinib (Sutent) remains a standard treatment in the first-line setting and is used as the control arm for multiple phase III trials. Pazopanib (Votrient) is a frontline standard therapy that is similar to sunitinib but may be better tolerated depending on the scheduling, states Choueiri.

There is a subgroup of patients that have certain mutations that are showing high response rates to everolimus (Afinitor), explains Choueiri.



Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the current therapies for patients with kidney cancer.

Sunitinib (Sutent) remains a standard treatment in the first-line setting and is used as the control arm for multiple phase III trials. Pazopanib (Votrient) is a frontline standard therapy that is similar to sunitinib but may be better tolerated depending on the scheduling, states Choueiri.

There is a subgroup of patients that have certain mutations that are showing high response rates to everolimus (Afinitor), explains Choueiri.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x